دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
doi : 10.1016/S2665-9913(21)00418-5
Volume 4, Issue 3, March 2022, Pages e154-e155
Wider considerations following evaluation of the STAR care pathway for patients with painful knee replacement
David Beard a
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus
Tanja Stamm a c, Ioannis Parodis d e, Paul Studenic b d
Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis
Laure Gossec a b
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries
doi : 10.1016/S2665-9913(21)00368-4
Volume 4, Issue 3, March 2022, Pages e160-e163
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
doi : 10.1016/S2665-9913(21)00393-3
Volume 4, Issue 3, March 2022, Pages e163-e166
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective
T J van Wesemael a, T W J Huizinga a, R E M Toes a, D van der Woude a
Call for papers: Sex and gender in rheumatology
Heather Van Epps a, Anna Clark a, Anna-Maria Hoffmann-Vold b, Oliver Distler c
Thank you to our peer reviewers in 2021
doi : 10.1016/S2665-9913(22)00037-6
Volume 4, Issue 3, March 2022, Pages e168-e169
Health-care workers recovered from natural SARS-CoV-2 infection should be exempt from mandatory vaccination edicts
doi : 10.1016/S2665-9913(22)00038-8
Volume 4, Issue 3, March 2022, Page e170
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1
doi : 10.1016/S2665-9913(22)00027-3
Volume 4, Issue 3, March 2022, Pages e171-e172
Severe COVID-19 as a virus-independent immunothrombotic process
doi : 10.1016/S2665-9913(22)00033-9
Volume 4, Issue 3, March 2022, Pages e172-e173
Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply
doi : 10.1016/S2665-9913(22)00031-5
Volume 4, Issue 3, March 2022, Page e173
Correction to Lancet Rheumatol 2021; 3: e789–97
doi : 10.1016/S2665-9913(22)00025-X
Volume 4, Issue 3, March 2022, Page e174
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
doi : 10.1016/S2665-9913(21)00394-5
Volume 4, Issue 3, March 2022, Pages e177-e187
The STAR care pathway for patients with pain at 3 months after total knee replacement: a multicentre, pragmatic, randomised, controlled trial
doi : 10.1016/S2665-9913(21)00371-4
Volume 4, Issue 3, March 2022, Pages e188-e197
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
Prof Vibeke Strand MD a, Sean O’Quinn MD b, Prof Richard A Furie MD d, Prof Eric F Morand MBBS e, Prof Kenneth C Kalunian MD f, Erik G Schwetje BS c, Gabriel Abreu PhD g, Raj Tummala MD c
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
Prof Vibeke Strand MD a, Prof Gurjit S Kaeley MD b, Prof Martin J Bergman MD c, Prof Dafna D Gladman MD d, Laura C Coates PhD e, Bintu Sherif MS f, Peter Hur PharmD g, Bhumik Parikh PharmD g, Isabelle Gilloteau MSc g, Prof Philip J Mease MD h i
The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice
Julia Day BMBS a, Anna Antony MBBS b, William Tillett PhD a c, Laura C Coates PhD d
